SCHEMBL9974151

SCHEMBL9974151

CC(=O)CN1CCCc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 7/20 0.68
CHRM4 P08173 7/20 0.68
CHRM1 P11229 7/20 0.68
CHRM3 P20309 7/20 0.68
ALDH1A1 P00352 6/20 0.67
GAA P10253 1/20 0.67
NOTUM Q6P988 1/20 0.59
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
ALPL P05186 1/20 0.58
ALPG P10696 1/20 0.58
MAPT P10636 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HPGD P15428 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22651884 0.90 MEN1 (0.59) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL28065937 0.87 CHRM2 (0.63) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL1102038 0.85 CHRM2 (0.70) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL4700798 0.84 ALDH1A1 (0.71) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL9664090 0.84 CHRM2 (0.60) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL5859908 0.83 ALDH1A1 (0.66) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL28643439 0.81 CHRM2 (1.00) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL21515338 0.81 CHRM2 (0.74) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL29930459 0.81 CHRM2 (1.00) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL11671841 0.81 ALPL (0.70) CHRM2CHRM4CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-20 US disclosed
US-8202861-B2 Drugs for various disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-19 US disclosed
US-20100221251-A1 Compositions and Methods for Treatment of Cancer ARQULE, INC. (US) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238578-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS SCNN1G, KCNN3, KCNN2 CHRM2 1093/4885CHRM4 1075/4885CHRM1 1682/4885
US-20100221251-A1 Compositions and Methods for Treatment of Cancer PDCD5, TP53, NUP205 CHRM2 4536/4885CHRM4 4573/4885CHRM1 4461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.